Published in J Neurol Neurosurg Psychiatry on June 21, 2009
Radial diffusivity predicts demyelination in ex vivo multiple sclerosis spinal cords. Neuroimage (2011) 2.02
Spinal cord tract diffusion tensor imaging reveals disability substrate in demyelinating disease. Neurology (2013) 1.77
The current state-of-the-art of spinal cord imaging: applications. Neuroimage (2013) 1.13
Diffusion imaging in multiple sclerosis: research and clinical implications. NMR Biomed (2010) 1.13
Multiparametric MRI correlates of sensorimotor function in the spinal cord in multiple sclerosis. Mult Scler (2012) 1.08
Spinal cord MRI in multiple sclerosis--diagnostic, prognostic and clinical value. Nat Rev Neurol (2015) 1.01
DTI Measurements in Multiple Sclerosis: Evaluation of Brain Damage and Clinical Implications. Mult Scler Int (2013) 0.99
Increased radial diffusivity in spinal cord lesions in neuromyelitis optica compared with multiple sclerosis. Mult Scler (2012) 0.97
Visual pathway axonal loss in benign multiple sclerosis: a longitudinal study. J Neuroophthalmol (2012) 0.90
Advanced diffusion-weighted magnetic resonance imaging techniques of the human spinal cord. Top Magn Reson Imaging (2010) 0.88
Diffusion tensor imaging detects treatment effects of FTY720 in experimental autoimmune encephalomyelitis mice. NMR Biomed (2013) 0.85
Translating state-of-the-art spinal cord MRI techniques to clinical use: A systematic review of clinical studies utilizing DTI, MT, MWF, MRS, and fMRI. Neuroimage Clin (2015) 0.84
Axonal degeneration in multiple sclerosis: can we predict and prevent permanent disability? Acta Neuropathol Commun (2014) 0.78
"Benign" and "normal appearing": it's in the eye of the beholder. J Neurol Neurosurg Psychiatry (2010) 0.77
White matter damage is related to ataxia severity in SCA3. J Neurol (2013) 0.77
The Role of T1-Weighted Derived Measures of Neurodegeneration for Assessing Disability Progression in Multiple Sclerosis. Front Neurol (2017) 0.75
Human mitochondrial DNA deletions associated with mutations in the gene encoding Twinkle, a phage T7 gene 4-like protein localized in mitochondria. Nat Genet (2001) 5.09
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet (2001) 4.55
Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain (1997) 3.87
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol (2009) 3.37
Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler (2008) 3.28
The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology (2003) 3.21
Central nervous system sarcoidosis--diagnosis and management. QJM (1999) 3.11
White matter damage in Alzheimer's disease assessed in vivo using diffusion tensor magnetic resonance imaging. J Neurol Neurosurg Psychiatry (2002) 2.72
Diffusion tensor magnetic resonance imaging in multiple sclerosis. Neurology (2001) 2.24
Consensus recommendations for MS cortical lesion scoring using double inversion recovery MRI. Neurology (2011) 2.17
Pattern of brain tissue loss associated with freezing of gait in Parkinson disease. Neurology (2012) 2.13
Reliability of the North Star Ambulatory Assessment in a multicentric setting. Neuromuscul Disord (2009) 2.13
Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study. Neurology (2011) 2.06
Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects. Neurology (2004) 2.04
Default-mode network dysfunction and cognitive impairment in progressive MS. Neurology (2010) 2.03
Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol (2001) 2.00
Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology (2003) 1.94
More on the effect of atorvastatin on plasma fibrinogen levels in primary hypercholesterolemia. Atherosclerosis (1999) 1.94
A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol (2011) 1.93
Ataxia with isolated vitamin E deficiency: neurological phenotype, clinical follow-up and novel mutations in TTPA gene in Italian families. Neurol Sci (2004) 1.92
MRI criteria for MS in patients with clinically isolated syndromes. Neurology (2010) 1.90
Cortical/subcortical disease burden and cognitive impairment in patients with multiple sclerosis. AJNR Am J Neuroradiol (2000) 1.88
Cognitive and psychosocial features of childhood and juvenile MS. Neurology (2008) 1.85
Cognitive and psychosocial features in childhood and juvenile MS: two-year follow-up. Neurology (2010) 1.85
Paraplegia following coeliac plexus block. Pain (1993) 1.85
Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment. Mult Scler (2005) 1.81
Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis. Neurology (2008) 1.80
Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology (2009) 1.78
Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes". Neurology (2001) 1.76
Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology (2008) 1.76
Correlation of multiple sclerosis measures derived from T2-weighted, T1-weighted, magnetization transfer, and diffusion tensor MR imaging. AJNR Am J Neuroradiol (2001) 1.75
An information aid for newly diagnosed multiple sclerosis patients improves disease knowledge and satisfaction with care. Mult Scler (2010) 1.74
The contribution of voxel-based morphometry in staging patients with mild cognitive impairment. Neurology (2006) 1.72
Autoantibodies to glutamic acid decarboxylase in palatal myoclonus and epilepsy. Ann Neurol (1994) 1.72
Asebia-2J (Scd1(ab2J)): a new allele and a model for scarring alopecia. Am J Pathol (2000) 1.71
Evidence for relative cortical sparing in benign multiple sclerosis: a longitudinal magnetic resonance imaging study. Mult Scler (2008) 1.70
Characterizing the mechanisms of progression in multiple sclerosis: evidence and new hypotheses for future directions. Arch Neurol (2005) 1.69
A method for obtaining tract-specific diffusion tensor MRI measurements in the presence of disease: application to patients with clinically isolated syndromes suggestive of multiple sclerosis. Neuroimage (2005) 1.68
Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. Neurology (2011) 1.68
Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol (2000) 1.66
Multiple sclerosis in childhood: clinical features of 149 cases. Mult Scler (1997) 1.65
Relating functional changes during hand movement to clinical parameters in patients with multiple sclerosis in a multi-centre fMRI study. Eur J Neurol (2008) 1.63
Evidence of thalamic gray matter loss in pediatric multiple sclerosis. Neurology (2008) 1.63
Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS. Neurology (2007) 1.62
Predictive markers for response to interferon therapy in patients with multiple sclerosis. Neurology (2008) 1.60
Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain (2003) 1.60
Variable responses to rituximab treatment in neuromyelitis optica (Devic's disease). Neurol Sci (2007) 1.59
Regional patterns of brain tissue loss associated with depression in Parkinson disease. Neurology (2010) 1.58
Voxelwise assessment of the regional distribution of damage in the brains of patients with multiple sclerosis and fatigue. AJNR Am J Neuroradiol (2011) 1.58
Denaturing gradient gel electrophoresis analysis of the 16S rRNA gene V1 region to monitor dynamic changes in the bacterial population during fermentation of Italian sausages. Appl Environ Microbiol (2001) 1.57
Spatial mapping of T2 and gadolinium-enhancing T1 lesion volumes in multiple sclerosis: evidence for distinct mechanisms of lesion genesis? Brain (1999) 1.56
Electrophysiological and MRI evaluation of neurological involvement in Behçet's disease. J Neurol Neurosurg Psychiatry (1989) 1.54
Comparison of three MR sequences for the detection of cervical cord lesions in patients with multiple sclerosis. AJNR Am J Neuroradiol (1999) 1.54
Optic nerve involvement in acute lymphoblastic leukemia. Leuk Lymphoma (1993) 1.52
Impedance measurements to study the antimicrobial activity of essential oils from Lamiaceae and Compositae. Int J Food Microbiol (2001) 1.52
Magnetic resonance imaging, magnetisation transfer imaging, and diffusion weighted imaging correlates of optic nerve, brain, and cervical cord damage in Leber's hereditary optic neuropathy. J Neurol Neurosurg Psychiatry (2001) 1.51
Younger age at diagnosis of type 1 diabetes mellitus in children of immigrated families born in Italy. J Endocrinol Invest (2004) 1.49
Diffusion MRI in multiple sclerosis. Neurology (2005) 1.49
In vivo assessment of cervical cord damage in MS patients: a longitudinal diffusion tensor MRI study. Brain (2007) 1.48
Global N-acetylaspartate declines even in benign multiple sclerosis. AJNR Am J Neuroradiol (2010) 1.47
Expression and regulation of IFNalpha/beta receptor in IFNbeta-treated patients with multiple sclerosis. Neurology (2008) 1.44
Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis. Neurology (2010) 1.44
Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis. Ann Neurol (1998) 1.44